aminolevulinic acid has been researched along with Benign Neoplasms in 117 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The excretion of delta-aminolevulinic acid and porphobilinogen in the urine of 31 patients with multiple sclerosis did not differ significantly from that of 51 hospitalized control patients or eight patients with poliomyelitis." | 7.64 | PORPHOBILINOGEN AND DELTA-AMINOLEVULINIC ACID EXCRETION IN MULTIPLE SCLEROSIS. ( MARKLE, V; PAZDER, LH; TAYLOR, JD, 1965) |
| "Whereas demyelination does occur in acute porphyria where the levels of delta-aminolevulinic acid and porphobilinogen are elevated, the converse is not true; that is, demyelination is not always associated with an increase in the excretion of porphobilinogen or delta-aminolevulinic acid." | 5.24 | PORPHOBILINOGEN AND DELTA-AMINOLEVULINIC ACID EXCRETION IN MULTIPLE SCLEROSIS. ( MARKLE, V; PAZDER, LH; TAYLOR, JD, 1965) |
| "Human tumor cells of the lines WiDr (adenocarcinoma of the rectosigmoid colon), NHIK 3025 (carcinoma of the cervix), and V79 Chinese hamster fibroblasts were treated with 5-aminolevulinic acid (ALA) and ALA esterified to C1-C3 and C6-C8 chained aliphatic alcohols (ALA-esters)." | 3.69 | Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. ( Anholt, H; Berg, K; Gaullier, JM; Ma, LW; Moan, J; Peng, Q; Selbo, PK, 1997) |
| "The excretion of delta-aminolevulinic acid and porphobilinogen in the urine of 31 patients with multiple sclerosis did not differ significantly from that of 51 hospitalized control patients or eight patients with poliomyelitis." | 3.64 | PORPHOBILINOGEN AND DELTA-AMINOLEVULINIC ACID EXCRETION IN MULTIPLE SCLEROSIS. ( MARKLE, V; PAZDER, LH; TAYLOR, JD, 1965) |
| "Cancer is the leading cause of death worldwide and several anticancer therapies take advantage of the ability of reactive oxygen species to kill cancer cells." | 3.01 | Reactive Oxygen Species Produced by 5-Aminolevulinic Acid Photodynamic Therapy in the Treatment of Cancer. ( Curia, MC; D'Antonio, DL; Piattelli, A; Pignatelli, P; Umme, S, 2023) |
| "5-aminolevulinic acid (5-ALA) is a widely used photosensitizer." | 3.01 | Nanoparticles drug delivery for 5-aminolevulinic acid (5-ALA) in photodynamic therapy (PDT) for multiple cancer treatment: a critical review on biosynthesis, detection, and therapeutic applications. ( Anjum, MM; Bhattacharya, S; Prajapati, BG; Singh, S, 2023) |
| "A better understanding of why cancer cells fluoresce with 5-ALA would improve its use in cancer diagnostics and therapies." | 2.61 | In order for the light to shine so brightly, the darkness must be present-why do cancers fluoresce with 5-aminolaevulinic acid? ( Gleadle, JM; MacGregor, MN; McNicholas, K, 2019) |
| "For example, breast cancer COH-BR1 and prostate cancer PC3 cells exhibited a rapid and prolonged upregulation of inducible nitric oxide synthase (iNOS) after sensitization with 5- aminolevulinic acid (ALA)-induced protoporphyrin-IX, followed by broad-band visible irradiation." | 2.53 | Multiple Means by Which Nitric Oxide can Antagonize Photodynamic Therapy. ( Fahey, JM; Girotti, AW; Korytowski, W, 2016) |
| "5-Aminolevulinic acid (5-ALA) is a naturally occurring amino acid and precursor of heme and protoporphyrin IX (PpIX)." | 2.53 | 5-Aminolevulinic acid regulates the inflammatory response and alloimmune reaction. ( Fujino, M; Ito, H; Li, XK; Nishio, Y; Tanaka, T, 2016) |
| "A variety of cancer imaging techniques have been adapted or developed for intraoperative surgical guidance that have been shown to improve functional and oncologic outcomes in randomized clinical trials." | 2.52 | The status of contemporary image-guided modalities in oncologic surgery. ( Bland, KI; Rosenthal, EL; Warram, JM; Zinn, KR, 2015) |
| "Because tumors and other proliferating cells tend to exhibit a higher level of PpIX than normal cells after ALA incubation, ALA has been used as a prodrug to enable PpIX fluorescence detection and photodynamic therapy (PDT) of lesion tissues." | 2.52 | Aminolevulinic Acid-Based Tumor Detection and Therapy: Molecular Mechanisms and Strategies for Enhancement. ( Chen, B; Kraus, D; Palasuberniam, P; Yang, X, 2015) |
| "Aminolevulinic acid (ALA) is a heme precursor that may have potential applications for photodynamic detection and photodynamic therapy-based treatment of solid tumors in a variety of malignancies." | 2.49 | Aminolevulinic acid (ALA): photodynamic detection and potential therapeutic applications. ( Apel, M; Brown, G; Jones, C; Lang, JE; Nokes, B, 2013) |
| "The first 20 years of anticancer photodynamic therapy (PDT) were based on the utility of the oligomeric mixture haematoporphyrin derivative (HpD) in various forms." | 2.44 | Photodynamic therapy: the development of new photosensitisers. ( Wainwright, M, 2008) |
| "Early cancer diagnosis is of the most crucial factors determining proper patient management and long-term survival." | 2.43 | Fluorescence diagnosis using enzyme-related metabolic abnormalities of neoplasia. ( Campo, MA; Lange, N, 2006) |
| "Photodynamic therapy (PDT) for cancer patients has developed into an important new clinical treatment modality in the past 25-years." | 2.40 | 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. ( Berg, K; Giercksky, KE; Kongshaug, M; Moan, J; Nesland, JM; Peng, Q; Warloe, T, 1997) |
| "Its use in the treatment of psoriasis has been attempted only quite recently and some modest success achieved." | 2.39 | Photodynamic therapy for psoriasis? ( Fergin, P, 1996) |
| "Dying cancer cells induced by 5-ALA-PDT efficiently activated bone-marrow derived dendritic cells (BMDCs)." | 1.91 | 5-ALA mediated photodynamic therapy with combined treatment improves anti-tumor efficacy of immunotherapy through boosting immunogenic cell death. ( Hong, L; Li, J; Lu, S; Luo, G; Sun, Z; Tang, Y; Wang, J; Wang, W; Wu, Z; Zhang, L; Zhang, Y; Zhao, M, 2023) |
| "Here, we design a cancer-motivated upconversion nanomachine (UCNM) based on porous upconversion nanoparticles (p-UCNPs) for precise phototherapy." | 1.91 | In-Tumor Biosynthetic Construction of Upconversion Nanomachines for Precise Near-Infrared Phototherapy. ( Gao, Y; He, B; Li, W; Luan, X; Pan, Y; Song, Y; Wang, X; Wang, Y; Zeng, F; Zhou, D, 2023) |
| "We engrafted breast cancer nodules having various hormonal profiles onto the chorioallantoic membrane of the eggs." | 1.91 | A step ahead to enhancing routine breast cancer resection: Spheroid and hen's egg chorioallantoic membrane models to assess the photodynamic diagnosis efficiency of ALA and PSI-ALA-hex. ( Kiening, M; Lange, N, 2023) |
| "Here, cancer-selective agents, i." | 1.72 | Cancer therapy by antibody-targeted Cerenkov light and metabolism-selective photosensitization. ( Ahn, H; Jo, C; Kang, CS; Kim, JH; Kim, JY; Kim, S; Lee, KC; Lee, YJ, 2022) |
| "Recent studies showed that a novel anti-cancer drug, Alectinib, an orally available, highly selective, potent second-generation inhibitor of anaplastic lymphoma tyrosinkinase binds to ferrochelatase." | 1.62 | Alectinib treatment improves photodynamic therapy in cancer cell lines of different origin. ( Essmann, F; Gillissen, B; Kemmner, W; Richter, A, 2021) |
| "We established a malignancy model by gradually increasing the cell density of cancer cells." | 1.62 | Efficiency of aminolevulinic acid (ALA)-photodynamic therapy based on ALA uptake transporters in a cell density-dependent malignancy model. ( Lai, HW; Nakajima, M; Ogura, SI; Takahashi, K; Tanaka, T, 2021) |
| "Photodynamic therapy (PDT) against tumors was performed under 635 nm laser irradiation." | 1.56 | Amylase-Protected Ag Nanodots for in vivo Fluorescence Imaging and Photodynamic Therapy of Tumors. ( He, P; Liu, R; Wang, W; Wen, S, 2020) |
| "Tumors were visualized in the near-infrared (NIR) region with reduced background noise." | 1.56 | Amylase-Protected Ag Nanodots for in vivo Fluorescence Imaging and Photodynamic Therapy of Tumors. ( He, P; Liu, R; Wang, W; Wen, S, 2020) |
| "In mice with intradermal tumors that were orally administered ALA (200 mg/kg daily for 5 days), the tumor in each mouse was simultaneously irradiated (8 h/day for 5 days) using a wirelessly powered implantable green LED device (532 nm, 0." | 1.56 | Metronomic photodynamic therapy using an implantable LED device and orally administered 5-aminolevulinic acid. ( Fujie, T; Fujita, K; Kirino, I; Morimoto, Y; Sakanoue, K; Sugita, R; Takeoka, S; Uemoto, S; Yamagishi, K, 2020) |
| "Photodynamic therapy (PDT) is a cancer treatment involving the generation of reactive oxygen species (ROS) by laser irradiation of porphyrins that accumulate in cancer tissues." | 1.51 | The Cisplatin-Derived Increase of Mitochondrial Reactive Oxygen Species Enhances the Effectiveness of Photodynamic Therapy via Transporter Regulation. ( Ito, H; Kurokawa, H; Matsui, H, 2019) |
| "Cancer cells and mice models of cancer were treated with 5-ALA-PDT, MEK inhibitor or both MEK inhibitor and 5-ALA-PDT, and treatment efficacies were evaluated." | 1.51 | Systemic MEK inhibition enhances the efficacy of 5-aminolevulinic acid-photodynamic therapy. ( Chelakkot, VS; Hirasawa, K; Rice, CP; Rutihinda, SG; Som, J; Yoshioka, E, 2019) |
| "The in vitro and in vivo anticancer results demonstrate that HA-PLGA@ART/ALA delivery system could provide a prospective comprehensive treatment strategy for cancer therapy." | 1.48 | Tumor-targeting core-shell structured nanoparticles for drug procedural controlled release and cancer sonodynamic combined therapy. ( Hao, Y; Hu, Y; Li, L; Niu, M; Wang, L; Yin, Y; Zhang, Y; Zhang, Z; Zhao, H; Zheng, C, 2018) |
| " They revealed a different fluorescence kinetics and dose-response curves for the different types of 5-ALA prodrugs." | 1.46 | Activity of phosphatase-sensitive 5-aminolevulinic acid prodrugs in cancer cell lines. ( Allémann, E; Babič, A; Herceg, V; Lange, N, 2017) |
| " However, chemical instability, low bioavailability and poor pharmacokinetic profile limit systemic efficacy of 5-ALA." | 1.46 | Activity of phosphatase-sensitive 5-aminolevulinic acid prodrugs in cancer cell lines. ( Allémann, E; Babič, A; Herceg, V; Lange, N, 2017) |
| " eEF1A1 was found to enrich ALA-induced PpIX in cells by competitively blocking the downstream bioavailability of PpIX." | 1.43 | eEF1A1 binds and enriches protoporphyrin IX in cancer cells in 5-aminolevulinic acid based photodynamic therapy. ( Cui, X; Fan, Z; He, H; Li, B; Liu, W; Wei, D; Wei, X; Ye, H; Zhu, N, 2016) |
| " However, the bioavailability of ALA is limited by its hydrophilic properties and limited cell uptake." | 1.42 | The use of dipeptide derivatives of 5-aminolaevulinic acid promotes their entry to tumor cells and improves tumor selectivity of photodynamic therapy. ( Batlle, A; Casas, A; Di Venosa, G; Eggleston, IM; Giuntini, F; Juarranz, A; MacRobert, AJ; Mamone, L; Vallecorsa, P; Vanzuli, S, 2015) |
| "Cancer is one of the most common and deadly diseases around the world." | 1.40 | Multi-channel LED light source for fluorescent agent aided minimally invasive surgery. ( Durfee, R; Kairdolf, B; Ren, J; Venugopalan, J; Wang, MD; Xu, J, 2014) |
| "Amongst all the different treatments of cancer such as surgery, chemotherapy and radiation therapy, surgical resection is the most effective." | 1.40 | Multi-channel LED light source for fluorescent agent aided minimally invasive surgery. ( Durfee, R; Kairdolf, B; Ren, J; Venugopalan, J; Wang, MD; Xu, J, 2014) |
| "(11)C-MALA in tumors was continuously decreased thereafter, and the elimination rate of (11)C-MALA from AsPC-1 tumors with the highest ALAD expression level was slower than from other tumors with lower expression levels." | 1.40 | Preclinical characterization of 5-amino-4-oxo-[6-11C]hexanoic acid as an imaging probe to estimate protoporphyrin IX accumulation induced by exogenous aminolevulinic acid. ( Arano, Y; Kato, K; Kikuchi, T; Okada, M; Saga, T; Sudo, H; Sugyo, A; Suzuki, C; Tsuji, AB; Zhang, MR, 2014) |
| "Higher ALA-induced PpIX fluorescence in cancer cell lines as compared to normal ones was not detected by all the methods used." | 1.39 | Factors implicated in the assessment of aminolevulinic acid-induced protoporphyrin IX fluorescence. ( Cunderlíková, B; Mateasík, A; Peng, Q, 2013) |
| "5-Aminolevulinic acid (ALA) is a natural, delta amino acid biosynthesized by animal and plant mitochondria." | 1.37 | Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy. ( Abe, F; Inoue, K; Ishizuka, M; Kohda, T; Komatsu, N; Nakajima, M; Ogura, S; Sano, Y; Takahashi, K; Tanaka, T, 2011) |
| "Experiments were carried out on cancerous HeLa cells and blood serum using a double integrating sphere and a He-Ne laser to investigate the optical properties and cellular effects due to photodynamic therapy (PDT)." | 1.36 | Laser-induced effects in different biological samples. ( Atif, M; Firdous, S; Nawaz, M, 2010) |
| "Human cancer cell lines (MCF-7 and HepG2) incubated in the dark in the simultaneous presence of 5." | 1.35 | Enhancement of 5-Aminolevulinic acid-induced oxidative stress on two cancer cell lines by gold nanoparticles. ( Degraff, WG; Ito, S; Kirschenbaum, LJ; Miyoshi, N; Nagashima, K; Riesz, P, 2009) |
| " Pharmacokinetic (PK) data from these individual studies were pooled and analyzed." | 1.33 | Clinical pharmacokinetics of the PDT photosensitizers porfimer sodium (Photofrin), 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (Photochlor) and 5-ALA-induced protoporphyrin IX. ( Bellnier, DA; Dougherty, TJ; Greco, WR; Loewen, GM; Nava, H; Oseroff, AR, 2006) |
| "Clinical trials of PDT at Roswell Park Cancer Institute (RPCI) use the photosensitizers Photofrin, Photochlor, and 5-ALA-induced protoporphyrin IX (PpIX)." | 1.33 | Clinical pharmacokinetics of the PDT photosensitizers porfimer sodium (Photofrin), 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (Photochlor) and 5-ALA-induced protoporphyrin IX. ( Bellnier, DA; Dougherty, TJ; Greco, WR; Loewen, GM; Nava, H; Oseroff, AR, 2006) |
| "5-aminolevulinic acid (5-ALA) is a precursor in synthesis of endogenous porphyrins used to sensitize tumor tissues in photodynamic therapy (PDT)." | 1.32 | Enhancement of photodynamic therapy by use of aminolevulinic acid/glycolic acid drug mixture. ( Bronowicz, A; Oremek, G; Osiecka, BJ; Saleh, Y; Siewinski, M; Symonowicz, K; Ziolkowski, P, 2004) |
| " It allows quasiquantitative testing of different protoporphyrin IX precursors with respect to dose-response curves and pharmacokinetics, as well as the evaluation of different incubation conditions and/or different drug formulations." | 1.31 | Routine experimental system for defining conditions used in photodynamic therapy and fluorescence photodetection of (non-) neoplastic epithelia. ( Etter, AL; Gerber, P; Jichlinski, P; Kucera, P; Lange, N; Marti, A; van Den Bergh, H; Vaucher, L, 2001) |
| "This study reports our first results of ambulant photodynamic treatment with 5-aminolevulinic acid (5-ALA) in combination with folic acid and subsequent illumination with a noncoherent light source." | 1.30 | Ambulant photodynamic therapy of superficial malignomas with 5-ALA in combination with folic acid and use of noncoherent light. ( Alth, G; Dobrowsky, W; Jindra, RH; Kolbabek, H; Kubin, A, 1999) |
| "Whereas demyelination does occur in acute porphyria where the levels of delta-aminolevulinic acid and porphobilinogen are elevated, the converse is not true; that is, demyelination is not always associated with an increase in the excretion of porphobilinogen or delta-aminolevulinic acid." | 1.24 | PORPHOBILINOGEN AND DELTA-AMINOLEVULINIC ACID EXCRETION IN MULTIPLE SCLEROSIS. ( MARKLE, V; PAZDER, LH; TAYLOR, JD, 1965) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (4.27) | 18.7374 |
| 1990's | 13 (11.11) | 18.2507 |
| 2000's | 30 (25.64) | 29.6817 |
| 2010's | 40 (34.19) | 24.3611 |
| 2020's | 29 (24.79) | 2.80 |
| Authors | Studies |
|---|---|
| Li, K | 1 |
| Dong, W | 1 |
| Qiu, L | 1 |
| Liu, Q | 1 |
| Lv, G | 1 |
| Peng, Y | 1 |
| Xie, M | 1 |
| Lin, J | 1 |
| Gillissen, B | 1 |
| Richter, A | 1 |
| Essmann, F | 1 |
| Kemmner, W | 1 |
| Sharma, KS | 1 |
| Dubey, AK | 1 |
| Kumar, C | 1 |
| Phadnis, PP | 1 |
| Sudarsan, V | 1 |
| Vatsa, RK | 1 |
| Mandruzzato, S | 1 |
| Della Puppa, A | 1 |
| Della Pepa, GM | 1 |
| Menna, G | 1 |
| Yan, Y | 1 |
| Li, Z | 2 |
| Tian, X | 1 |
| Zeng, X | 1 |
| Chen, Q | 1 |
| Wang, J | 3 |
| Kiening, M | 2 |
| Lange, N | 7 |
| Pétusseau, A | 1 |
| Bruza, P | 1 |
| Pogue, B | 2 |
| Jo, C | 1 |
| Ahn, H | 1 |
| Kim, JH | 1 |
| Lee, YJ | 1 |
| Kim, JY | 1 |
| Lee, KC | 1 |
| Kang, CS | 1 |
| Kim, S | 1 |
| Sun, Z | 2 |
| Zhao, M | 2 |
| Wang, W | 3 |
| Hong, L | 2 |
| Wu, Z | 2 |
| Luo, G | 2 |
| Lu, S | 2 |
| Tang, Y | 2 |
| Li, J | 2 |
| Zhang, Y | 3 |
| Zhang, L | 2 |
| Ivanova-Radkevich, VI | 2 |
| Islam, R | 1 |
| Kotalík, K | 1 |
| Šubr, V | 1 |
| Gao, S | 1 |
| Zhou, JR | 1 |
| Yokomizo, K | 1 |
| Etrych, T | 1 |
| Fang, J | 1 |
| Pan, Y | 1 |
| Luan, X | 1 |
| Gao, Y | 1 |
| Zeng, F | 1 |
| Wang, X | 1 |
| Zhou, D | 1 |
| Li, W | 1 |
| Wang, Y | 4 |
| He, B | 1 |
| Song, Y | 1 |
| Ogbonna, SJ | 2 |
| York, WY | 1 |
| Nishimura, T | 1 |
| Hazama, H | 2 |
| Fukuhara, H | 2 |
| Inoue, K | 3 |
| Awazu, K | 2 |
| Pignatelli, P | 1 |
| Umme, S | 1 |
| D'Antonio, DL | 1 |
| Piattelli, A | 1 |
| Curia, MC | 1 |
| Girotti, AW | 2 |
| Bazak, J | 1 |
| Korytowski, W | 2 |
| Sansaloni-Pastor, S | 1 |
| Bhattacharya, S | 1 |
| Prajapati, BG | 1 |
| Singh, S | 1 |
| Anjum, MM | 1 |
| McNicholas, K | 1 |
| MacGregor, MN | 1 |
| Gleadle, JM | 1 |
| Kurokawa, H | 1 |
| Ito, H | 2 |
| Matsui, H | 1 |
| Maytin, EV | 2 |
| Hasan, T | 2 |
| Ma, L | 1 |
| Yang, X | 3 |
| Yao, X | 1 |
| Weng, W | 1 |
| Casas, A | 5 |
| Lai, HW | 2 |
| Nakayama, T | 1 |
| Ogura, SI | 2 |
| Lim, MSH | 1 |
| Nishiyama, Y | 1 |
| Ohtsuki, T | 1 |
| Watanabe, K | 1 |
| Kobuchi, H | 1 |
| Kobayashi, K | 1 |
| Matsuura, E | 1 |
| Takahashi, K | 2 |
| Nakajima, M | 3 |
| Tanaka, T | 3 |
| Dashti Gerdabi, N | 1 |
| Ghafourian, M | 1 |
| Iranparast, S | 1 |
| Khodadadi, A | 1 |
| Azari, F | 1 |
| Kennedy, G | 1 |
| Bernstein, E | 1 |
| Hadjipanayis, C | 1 |
| Vahrmeijer, A | 1 |
| Smith, B | 1 |
| Rosenthal, E | 1 |
| Sumer, B | 1 |
| Tian, J | 1 |
| Henderson, E | 1 |
| Lee, A | 1 |
| Nguyen, Q | 1 |
| Gibbs, S | 1 |
| Orringer, D | 1 |
| Charalampaki, C | 1 |
| Martin, L | 1 |
| Tanyi, J | 1 |
| Lee, M | 1 |
| Lee, JY | 1 |
| Singhal, S | 1 |
| Wu, J | 1 |
| Han, H | 1 |
| Jin, Q | 1 |
| Li, H | 2 |
| Ji, J | 1 |
| Herceg, V | 1 |
| Allémann, E | 1 |
| Babič, A | 1 |
| Zhao, H | 2 |
| Yin, R | 1 |
| Lee, YH | 1 |
| Luo, T | 1 |
| Zhang, J | 1 |
| Qiu, H | 1 |
| Ambrose, S | 1 |
| Wang, L | 2 |
| Ren, J | 2 |
| Yao, J | 1 |
| Chen, D | 1 |
| Liang, Z | 1 |
| Zhen, J | 1 |
| Wu, S | 1 |
| Ye, Z | 1 |
| Zeng, J | 1 |
| Huang, N | 1 |
| Gu, Y | 1 |
| Yang, Y | 1 |
| Hu, Y | 2 |
| Du, H | 2 |
| Ren, L | 1 |
| Wang, H | 2 |
| Zheng, DW | 1 |
| Fan, JX | 1 |
| Liu, XH | 1 |
| Dong, X | 1 |
| Pan, P | 1 |
| Xu, L | 1 |
| Zhang, XZ | 1 |
| Zhao, X | 1 |
| Li, X | 1 |
| Zhang, P | 1 |
| Du, J | 1 |
| García Calavia, P | 1 |
| Bruce, G | 1 |
| Pérez-García, L | 1 |
| Russell, DA | 1 |
| Landes, R | 1 |
| Illanes, A | 1 |
| Goeppner, D | 1 |
| Gollnick, H | 1 |
| Friebe, M | 1 |
| Panariello, L | 1 |
| Donnarumma, M | 1 |
| Cinelli, E | 1 |
| Fabbrocini, G | 1 |
| Tewari, KM | 1 |
| Eggleston, IM | 2 |
| Kanehira, K | 1 |
| Yano, Y | 1 |
| Hasumi, H | 1 |
| Hanazaki, K | 1 |
| Yao, M | 1 |
| Knipps, J | 1 |
| Fischer, I | 1 |
| Neumann, LM | 1 |
| Rapp, M | 1 |
| Dibué-Adjei, M | 1 |
| Freiin von Saß, C | 1 |
| Placke, JM | 1 |
| Mijderwijk, HJ | 1 |
| Steiger, HJ | 1 |
| Sabel, M | 1 |
| Cornelius, JF | 1 |
| Kamp, MA | 1 |
| Gao, Z | 1 |
| Zheng, J | 1 |
| Yang, B | 1 |
| Wang, Z | 1 |
| Fan, H | 1 |
| Lv, Y | 1 |
| Jia, L | 1 |
| Cao, W | 1 |
| Nokes, B | 1 |
| Apel, M | 1 |
| Jones, C | 1 |
| Brown, G | 1 |
| Lang, JE | 1 |
| Suzuki, C | 2 |
| Kato, K | 2 |
| Tsuji, AB | 2 |
| Kikuchi, T | 2 |
| Zhang, MR | 2 |
| Arano, Y | 2 |
| Saga, T | 2 |
| Xie, H | 1 |
| Xie, Z | 1 |
| Mousavi, M | 1 |
| Bendsoe, N | 1 |
| Brydegaard, M | 1 |
| Axelsson, J | 1 |
| Andersson-Engels, S | 2 |
| Blázquez-Castro, A | 1 |
| Breitenbach, T | 1 |
| Ogilby, PR | 1 |
| Sudo, H | 1 |
| Okada, M | 1 |
| Sugyo, A | 1 |
| Di Venosa, G | 1 |
| Vallecorsa, P | 1 |
| Giuntini, F | 1 |
| Mamone, L | 1 |
| Batlle, A | 4 |
| Vanzuli, S | 1 |
| Juarranz, A | 1 |
| MacRobert, AJ | 1 |
| Venugopalan, J | 1 |
| Xu, J | 1 |
| Kairdolf, B | 1 |
| Durfee, R | 1 |
| Wang, MD | 1 |
| Rosenthal, EL | 2 |
| Warram, JM | 2 |
| Bland, KI | 1 |
| Zinn, KR | 1 |
| Palasuberniam, P | 1 |
| Kraus, D | 1 |
| Chen, B | 1 |
| Fujino, M | 1 |
| Nishio, Y | 1 |
| Li, XK | 1 |
| Fan, Z | 1 |
| Cui, X | 1 |
| Wei, D | 1 |
| Liu, W | 1 |
| Li, B | 1 |
| He, H | 1 |
| Ye, H | 1 |
| Zhu, N | 1 |
| Wei, X | 1 |
| Lopez, N | 1 |
| Mulet, R | 1 |
| Rodríguez, R | 1 |
| Yonemura, Y | 1 |
| Canbay, E | 1 |
| Ishibashi, H | 1 |
| Nishino, E | 1 |
| Endou, Y | 1 |
| Sako, S | 1 |
| Ogura, S | 3 |
| Fahey, JM | 1 |
| Hagiya, Y | 1 |
| Adachi, T | 1 |
| An, R | 1 |
| Tamura, A | 1 |
| Nakagawa, H | 1 |
| Okura, I | 1 |
| Mochizuki, T | 1 |
| Ishikawa, T | 1 |
| Oo, MK | 1 |
| Osiecka, B | 1 |
| Jurczyszyn, K | 1 |
| Symonowicz, K | 2 |
| Bronowicz, A | 2 |
| Ziolkowski, P | 2 |
| Ito, S | 1 |
| Miyoshi, N | 1 |
| Degraff, WG | 1 |
| Nagashima, K | 1 |
| Kirschenbaum, LJ | 1 |
| Riesz, P | 1 |
| Atif, M | 1 |
| Firdous, S | 1 |
| Nawaz, M | 1 |
| Allison, RR | 1 |
| Bagnato, VS | 1 |
| Sibata, CH | 1 |
| Ishizuka, M | 1 |
| Abe, F | 1 |
| Sano, Y | 1 |
| Kohda, T | 1 |
| Komatsu, N | 1 |
| Berg, K | 3 |
| Golab, J | 1 |
| Korbelik, M | 1 |
| Russell, D | 1 |
| Musiol, R | 1 |
| Serda, M | 1 |
| Polanski, J | 1 |
| Anand, S | 1 |
| Ortel, BJ | 1 |
| Pereira, SP | 1 |
| Cunderlíková, B | 1 |
| Peng, Q | 3 |
| Mateasík, A | 1 |
| Hui, SW | 1 |
| Kelty, CJ | 1 |
| Brown, NJ | 1 |
| Reed, MW | 1 |
| Ackroyd, R | 2 |
| Wu, SM | 1 |
| Ren, QG | 1 |
| Zhou, MO | 1 |
| Wei, Y | 1 |
| Chen, JY | 1 |
| TSCHUDY, DP | 1 |
| COLLINS, A | 1 |
| HANO, K | 1 |
| AKASHI, A | 1 |
| SCHLENKER, FS | 1 |
| TAYLOR, NA | 1 |
| KIEHN, BP | 1 |
| TAYLOR, JD | 1 |
| PAZDER, LH | 1 |
| MARKLE, V | 1 |
| Collaud, S | 1 |
| Juzeniene, A | 1 |
| Moan, J | 3 |
| Fukuda, H | 2 |
| Osiecka, BJ | 1 |
| Oremek, G | 1 |
| Siewinski, M | 1 |
| Saleh, Y | 1 |
| Sabban, F | 1 |
| Collinet, P | 1 |
| Cosson, M | 1 |
| Mordon, S | 1 |
| Kang, MS | 1 |
| Kim, DM | 1 |
| Kim, JS | 1 |
| Jeong, JH | 1 |
| Campo, MA | 1 |
| Bellnier, DA | 1 |
| Greco, WR | 1 |
| Loewen, GM | 1 |
| Nava, H | 1 |
| Oseroff, AR | 1 |
| Dougherty, TJ | 2 |
| Silva, JN | 1 |
| Filipe, P | 1 |
| Morlière, P | 1 |
| Mazière, JC | 1 |
| Freitas, JP | 1 |
| Cirne de Castro, JL | 1 |
| Santus, R | 1 |
| Al-Waili, NS | 1 |
| Butler, GJ | 1 |
| Dietel, W | 1 |
| Pottier, R | 1 |
| Pfister, W | 1 |
| Schleier, P | 1 |
| Zinner, K | 1 |
| Schneider, R | 1 |
| Tirand, L | 1 |
| Frochot, C | 1 |
| Vanderesse, R | 1 |
| Thomas, N | 1 |
| Gravier, J | 1 |
| Guillemin, F | 1 |
| Barberi-Heyob, M | 1 |
| Heinemann, IU | 1 |
| Jahn, M | 1 |
| Jahn, D | 1 |
| Vallinayagam, R | 1 |
| Schmitt, F | 1 |
| Barge, J | 1 |
| Wagnieres, G | 1 |
| Wenger, V | 1 |
| Neier, R | 1 |
| Juillerat-Jeanneret, L | 1 |
| Krammer, B | 1 |
| Plaetzer, K | 1 |
| Wainwright, M | 1 |
| Batlle, AM | 1 |
| Fergin, P | 1 |
| Sroka, R | 1 |
| Beyer, W | 1 |
| Gossner, L | 1 |
| Sassy, T | 1 |
| Stocker, S | 1 |
| Baumgartner, R | 1 |
| Egger, NG | 1 |
| Motamedi, M | 1 |
| Pow-Sang, M | 1 |
| Orihuela, E | 1 |
| Anderson, KE | 1 |
| Gaullier, JM | 1 |
| Anholt, H | 1 |
| Selbo, PK | 1 |
| Ma, LW | 1 |
| Warloe, T | 1 |
| Kongshaug, M | 1 |
| Giercksky, KE | 1 |
| Nesland, JM | 1 |
| Marcus, SL | 1 |
| Sobel, RS | 1 |
| Golub, AL | 1 |
| Carroll, RL | 1 |
| Lundahl, S | 1 |
| Shulman, DG | 1 |
| Svanberg, K | 1 |
| Wang, I | 1 |
| Colleen, S | 1 |
| Idvall, I | 1 |
| Ingvar, C | 1 |
| Rydell, R | 1 |
| Jocham, D | 1 |
| Diddens, H | 1 |
| Bown, S | 1 |
| Gregory, G | 1 |
| Montán, S | 1 |
| Svanberg, S | 1 |
| Apostoli, P | 1 |
| Muzyka, V | 2 |
| Veimer, S | 1 |
| Schmidt, N | 1 |
| Jindra, RH | 1 |
| Kubin, A | 1 |
| Kolbabek, H | 1 |
| Alth, G | 1 |
| Dobrowsky, W | 1 |
| Gibson, SL | 1 |
| Nguyen, ML | 1 |
| Havens, JJ | 1 |
| Barbarin, A | 1 |
| Hilf, R | 1 |
| Fuchs, J | 1 |
| Weber, S | 1 |
| Kaufmann, R | 1 |
| Koenig, F | 1 |
| Knittel, J | 1 |
| Stepp, H | 1 |
| Vaucher, L | 1 |
| Marti, A | 1 |
| Etter, AL | 1 |
| Gerber, P | 1 |
| van Den Bergh, H | 1 |
| Jichlinski, P | 1 |
| Kucera, P | 1 |
| Kelty, C | 1 |
| Brown, N | 1 |
| Reed, M | 1 |
| Bogovski, S | 1 |
| Viitak, A | 1 |
| Veidebaum, T | 1 |
| Karbownik, M | 1 |
| Reiter, RJ | 1 |
| Maruna, RF | 1 |
| Michalica, W | 1 |
| Chelakkot, VS | 1 |
| Som, J | 1 |
| Yoshioka, E | 1 |
| Rice, CP | 1 |
| Rutihinda, SG | 1 |
| Hirasawa, K | 1 |
| Wen, S | 1 |
| Liu, R | 1 |
| He, P | 1 |
| Kirino, I | 1 |
| Fujita, K | 1 |
| Sakanoue, K | 1 |
| Sugita, R | 1 |
| Yamagishi, K | 1 |
| Takeoka, S | 1 |
| Fujie, T | 1 |
| Uemoto, S | 1 |
| Morimoto, Y | 1 |
| Hao, Y | 1 |
| Li, L | 1 |
| Zheng, C | 1 |
| Niu, M | 1 |
| Yin, Y | 1 |
| Zhang, Z | 1 |
| Zhang, RR | 1 |
| Schroeder, AB | 1 |
| Grudzinski, JJ | 1 |
| Pinchuk, AN | 1 |
| Eliceiri, KW | 1 |
| Kuo, JS | 1 |
| Weichert, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Portable Measurement of Protoporphyrin IX in the Skin[NCT04223570] | 218 participants (Anticipated) | Observational | 2022-12-01 | Enrolling by invitation | |||
| Prospective Study on the Contribution of Fluorescence in the Guidance of Lymphadenectomy and in Peroperative Evaluation of Pre-anastomotic Tissue Perfusion in Laparoscopic Esogastric Oncologic Resections[NCT04734821] | 60 participants (Anticipated) | Interventional | 2021-04-01 | Recruiting | |||
| Influence of Radiation Patterns Following Circadian Rhythm Upon Response of Radiotherapy of Uterine Cervical Cancer : Melatonin as a Radiosensitivity and Biological Marker[NCT05511740] | 71 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
46 reviews available for aminolevulinic acid and Benign Neoplasms
| Article | Year |
|---|---|
Letter to the Editor Regarding "5-Aminolevulinic Acid False Positives in Cerebral Neuro-Oncology: Not All That Is Fluorescent Is Tumor. A Case-Based Update and Literature Review".
Topics: Aminolevulinic Acid; Coloring Agents; Humans; Neoplasms | 2022 |
In Reply to the Letter to the Editor Regarding "5-Aminolevulinic Acid False Positives in Cerebral Neuro-Oncology: Not All That Is Fluorescent Is Tumor. A Case-Based Update and Literature Review".
Topics: Aminolevulinic Acid; Coloring Agents; Humans; Neoplasms | 2022 |
A Recap of Heme Metabolism towards Understanding Protoporphyrin IX Selectivity in Cancer Cells.
Topics: Aminolevulinic Acid; Animals; Heme; Iron; Mammals; Neoplasms; Porphyrins; Protoporphyrins | 2022 |
Biochemical Basis of Selective Accumulation and Targeted Delivery of Photosensitizers to Tumor Tissues.
Topics: Aminolevulinic Acid; Humans; Indoles; Neoplasms; Photochemotherapy; Photosensitizing Agents | 2022 |
Biochemical Basis of Selective Accumulation and Targeted Delivery of Photosensitizers to Tumor Tissues.
Topics: Aminolevulinic Acid; Humans; Indoles; Neoplasms; Photochemotherapy; Photosensitizing Agents | 2022 |
Biochemical Basis of Selective Accumulation and Targeted Delivery of Photosensitizers to Tumor Tissues.
Topics: Aminolevulinic Acid; Humans; Indoles; Neoplasms; Photochemotherapy; Photosensitizing Agents | 2022 |
Biochemical Basis of Selective Accumulation and Targeted Delivery of Photosensitizers to Tumor Tissues.
Topics: Aminolevulinic Acid; Humans; Indoles; Neoplasms; Photochemotherapy; Photosensitizing Agents | 2022 |
Reactive Oxygen Species Produced by 5-Aminolevulinic Acid Photodynamic Therapy in the Treatment of Cancer.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents | 2023 |
Pro-Tumor Activity of Endogenous Nitric Oxide in Anti-Tumor Photodynamic Therapy: Recently Recognized Bystander Effects.
Topics: Aminolevulinic Acid; Bystander Effect; Cell Line, Tumor; Humans; Neoplasms; Nitric Oxide; Photochemo | 2023 |
Nanoparticles drug delivery for 5-aminolevulinic acid (5-ALA) in photodynamic therapy (PDT) for multiple cancer treatment: a critical review on biosynthesis, detection, and therapeutic applications.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Humans; Nanoparticles; Neoplasms; Photochemotherapy; Photosen | 2023 |
In order for the light to shine so brightly, the darkness must be present-why do cancers fluoresce with 5-aminolaevulinic acid?
Topics: Amino Acid Transport Systems; Aminolevulinic Acid; Brain Neoplasms; Coproporphyrinogens; Ferrochelat | 2019 |
Vitamin D and Other Differentiation-promoting Agents as Neoadjuvants for Photodynamic Therapy of Cancer.
Topics: Administration, Oral; Aminolevulinic Acid; Cell Differentiation; Fluorouracil; Humans; Methotrexate; | 2020 |
Clinical uses of 5-aminolaevulinic acid in photodynamic treatment and photodetection of cancer: A review.
Topics: Aminolevulinic Acid; Animals; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents | 2020 |
Key transporters leading to specific protoporphyrin IX accumulation in cancer cell following administration of aminolevulinic acid in photodynamic therapy/diagnosis.
Topics: Aminolevulinic Acid; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents; Protoporphyrins | 2021 |
Intraoperative molecular imaging clinical trials: a review of 2020 conference proceedings.
Topics: Aminolevulinic Acid; Humans; Margins of Excision; Molecular Imaging; Neoplasms | 2021 |
Photosensitiser-gold nanoparticle conjugates for photodynamic therapy of cancer.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Cell Proliferation; Gold; Humans; Metal Nanoparticles; N | 2018 |
Chemical approaches for the enhancement of 5-aminolevulinic acid-based photodynamic therapy and photodiagnosis.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Humans; Neoplasms; Photochemotherapy; Photosensitizing A | 2018 |
Aminolevulinic acid (ALA): photodynamic detection and potential therapeutic applications.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Drug Administration Routes; Drug Approval; Humans; Neopl | 2013 |
The status of contemporary image-guided modalities in oncologic surgery.
Topics: Aminolevulinic Acid; Brain Neoplasms; Coloring Agents; Diagnostic Imaging; Fluorescent Dyes; Humans; | 2015 |
Aminolevulinic Acid-Based Tumor Detection and Therapy: Molecular Mechanisms and Strategies for Enhancement.
Topics: Aminolevulinic Acid; Animals; Heme; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents; P | 2015 |
5-Aminolevulinic acid regulates the inflammatory response and alloimmune reaction.
Topics: Aminolevulinic Acid; Heme; Heme Oxygenase-1; Histocompatibility; Humans; Immunity; Immunologic Facto | 2016 |
Multiple Means by Which Nitric Oxide can Antagonize Photodynamic Therapy.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Humans; Light; Neoplasms; Nitric Oxide; Nitric Oxide Syntha | 2016 |
Future of oncologic photodynamic therapy.
Topics: Aminolevulinic Acid; Dihematoporphyrin Ether; Forecasting; Humans; Mesoporphyrins; Nanoparticles; Ne | 2010 |
Prodrugs in photodynamic anticancer therapy.
Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; Dihematoporphyrin Ether; Drug Design; Humans; I | 2011 |
Biomodulatory approaches to photodynamic therapy for solid tumors.
Topics: Aminolevulinic Acid; Humans; Methotrexate; Neoplasms; Oxygen; Photochemotherapy; Photosensitizing Ag | 2012 |
The application of electroporation to transfect hematopoietic cells and to deliver drugs and vaccines transcutaneously for cancer treatment.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Animals; Antigens, CD34; Antimetabolites, Antineopla | 2002 |
The use of 5-aminolaevulinic acid as a photosensitiser in photodynamic therapy and photodiagnosis.
Topics: Aminolevulinic Acid; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents | 2002 |
Rational design of 5-aminolevulinic acid derivatives aimed at improving photodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Biological Transport; Drug Design; Humans; Neoplasms; Photochemotherap | 2002 |
On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation.
Topics: Aminolevulinic Acid; Animals; Hematoporphyrin Photoradiation; Heme; Humans; Molecular Structure; Neo | 2004 |
Aminolevulinic acid: from its unique biological function to its star role in photodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Diagnostic Imaging; Humans; Neoplasms; Oxygen; Pest Control; Photochem | 2005 |
[Fluorescence imaging technique: diagnostic and therapeutic interest in gynecology].
Topics: Aminolevulinic Acid; Breast Neoplasms; Female; Genital Diseases, Female; Gynecology; Humans; Neoplas | 2004 |
Use of ALA and ALA derivatives for optimizing ALA-based photodynamic therapy: a review of our experience.
Topics: Aminolevulinic Acid; Animals; Esterases; Heme; Humans; Neoplasms; Photochemotherapy; Photosensitizin | 2006 |
Fluorescence diagnosis using enzyme-related metabolic abnormalities of neoplasia.
Topics: Aminolevulinic Acid; Animals; Diagnostic Imaging; Drug Delivery Systems; Fluorescence; Glycolysis; H | 2006 |
Photodynamic therapies: principles and present medical applications.
Topics: Aminolevulinic Acid; Bowen's Disease; Clinical Trials as Topic; Humans; Light; Lipoproteins, LDL; Ma | 2006 |
Recent improvements in the use of synthetic peptides for a selective photodynamic therapy.
Topics: Amino Acid Sequence; Aminolevulinic Acid; Antigens, Polyomavirus Transforming; Caspase 3; Drug Deliv | 2006 |
The biochemistry of heme biosynthesis.
Topics: Aminolevulinic Acid; Archaea; Bacteria; Heme; Herbicides; Models, Molecular; Neoplasms; Photochemoth | 2008 |
ALA and its clinical impact, from bench to bedside.
Topics: Aminolevulinic Acid; Dendritic Cells; Fluorescence; Humans; Keratosis; Lymphocytes; Macrophages; Neo | 2008 |
Photodynamic therapy: the development of new photosensitisers.
Topics: Aminolevulinic Acid; Animals; Humans; Indoles; Isoindoles; Mesoporphyrins; Neoplasms; Photochemother | 2008 |
Porphyrins, porphyrias, cancer and photodynamic therapy--a model for carcinogenesis.
Topics: Aminolevulinic Acid; Heme; Humans; Models, Biological; Neoplasms; Photochemotherapy; Porphyrias; Por | 1993 |
Photodynamic therapy.
Topics: Aminolevulinic Acid; Clinical Trials as Topic; Dihematoporphyrin Ether; Humans; Lasers; Mesoporphyri | 1993 |
Photodynamic therapy for psoriasis?
Topics: Aminolevulinic Acid; Humans; Neoplasms; Photochemotherapy; Psoriasis; Radiation-Sensitizing Agents; | 1996 |
5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges.
Topics: Aminolevulinic Acid; Forecasting; Heme; Humans; Neoplasms; Photochemotherapy; Protoporphyrins; Resea | 1997 |
Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status.
Topics: Aminolevulinic Acid; Animals; Endometrium; Female; Gastrointestinal Neoplasms; Humans; Laser Therapy | 1996 |
Clinical multi-colour fluorescence imaging of malignant tumours--initial experience.
Topics: Adult; Aminolevulinic Acid; Diagnostic Imaging; Female; Fluorescence; Hematoporphyrins; Humans; Imag | 1998 |
[Update on the subject of lead toxicology].
Topics: Abnormalities, Drug-Induced; Aminolevulinic Acid; Animals; Biomarkers; Cardiovascular Diseases; Coho | 1998 |
Genotoxic potential of porphyrin type photosensitizers with particular emphasis on 5-aminolevulinic acid: implications for clinical photodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Carcinogens; Humans; Mice; Mutagens; Neoplasms; Photochemotherapy; Pho | 2000 |
The history of photodetection and photodynamic therapy.
Topics: Aminolevulinic Acid; Hematoporphyrins; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents | 2001 |
Melatonin protects against oxidative stress caused by delta-aminolevulinic acid: implications for cancer reduction.
Topics: Aminolevulinic Acid; Animals; Anticarcinogenic Agents; Heme; Humans; Melatonin; Models, Biological; | 2002 |
Beyond the margins: real-time detection of cancer using targeted fluorophores.
Topics: Aminolevulinic Acid; Drug Discovery; Fluorescent Dyes; Humans; Indocyanine Green; Intraoperative Car | 2017 |
71 other studies available for aminolevulinic acid and Benign Neoplasms
| Article | Year |
|---|---|
A new GSH-responsive prodrug of 5-aminolevulinic acid for photodiagnosis and photodynamic therapy of tumors.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Glutathione; Humans; Levulinic Acids; Neoplasms; Optical Imag | 2019 |
Alectinib treatment improves photodynamic therapy in cancer cell lines of different origin.
Topics: Aminolevulinic Acid; Carbazoles; Fluorescence; Humans; Light; Neoplasms; Photochemotherapy; Photosen | 2021 |
Mesoporous Silica-Coated Upconversion Nanoparticles Assisted Photodynamic Therapy Using 5-Aminolevulinic Acid: Mechanistic and
Topics: Aminolevulinic Acid; Animals; Mice; Mice, SCID; Nanoparticles; Neoplasms; Photochemotherapy; Photose | 2022 |
Laser-assisted photodynamic therapy in proliferative verrucous oral leukoplakia.
Topics: Aminolevulinic Acid; Humans; Lasers; Leukoplakia, Oral; Neoplasms; Photochemotherapy; Photosensitizi | 2022 |
Protoporphyrin IX delayed fluorescence imaging: a modality for hypoxia-based surgical guidance.
Topics: Aminolevulinic Acid; Fluorescence; Humans; Hypoxia; Neoplasms; Oxygen; Photosensitizing Agents; Prot | 2022 |
Cancer therapy by antibody-targeted Cerenkov light and metabolism-selective photosensitization.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents | 2022 |
5-ALA mediated photodynamic therapy with combined treatment improves anti-tumor efficacy of immunotherapy through boosting immunogenic cell death.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Immunogenic Cell Death; Immunotherapy; Mice; Neoplas | 2023 |
5-ALA mediated photodynamic therapy with combined treatment improves anti-tumor efficacy of immunotherapy through boosting immunogenic cell death.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Immunogenic Cell Death; Immunotherapy; Mice; Neoplas | 2023 |
5-ALA mediated photodynamic therapy with combined treatment improves anti-tumor efficacy of immunotherapy through boosting immunogenic cell death.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Immunogenic Cell Death; Immunotherapy; Mice; Neoplas | 2023 |
5-ALA mediated photodynamic therapy with combined treatment improves anti-tumor efficacy of immunotherapy through boosting immunogenic cell death.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Immunogenic Cell Death; Immunotherapy; Mice; Neoplas | 2023 |
HPMA copolymer conjugated 5-aminolevulinic acid exhibits superior efficacy for photodynamic therapy with tumor-responsive and targeting properties.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Humans; Neoplasms; Photoc | 2023 |
In-Tumor Biosynthetic Construction of Upconversion Nanomachines for Precise Near-Infrared Phototherapy.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Humans; Infrared Rays; Nanoparticles; Neoplasms; Photochemoth | 2023 |
A step ahead to enhancing routine breast cancer resection: Spheroid and hen's egg chorioallantoic membrane models to assess the photodynamic diagnosis efficiency of ALA and PSI-ALA-hex.
Topics: Aminolevulinic Acid; Animals; Chick Embryo; Chickens; Chorioallantoic Membrane; Female; Neoplasms; P | 2023 |
Increased fluorescence observation intensity during the photodynamic diagnosis of deeply located tumors by fluorescence photoswitching of protoporphyrin IX.
Topics: Aminolevulinic Acid; Fluorescence; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pr | 2023 |
Unleashing the potential of 5-Aminolevulinic acid: Unveiling a promising target for cancer diagnosis and treatment beyond photodynamic therapy.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Heme; Humans; Male; Neoplasms; Photochemotherapy; Photosensit | 2023 |
The Cisplatin-Derived Increase of Mitochondrial Reactive Oxygen Species Enhances the Effectiveness of Photodynamic Therapy via Transporter Regulation.
Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, | 2019 |
Solubilization of Hexyl Aminolevulinate by Surfactants for Tumor Fluorescence Detection.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Feasibility Studies; Fluorescence; Heterografts; Hum | 2020 |
Lactosome-Conjugated siRNA Nanoparticles for Photo-Enhanced Gene Silencing in Cancer Cells.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Gene Silencing; Nanoparticles; Neoplasms; Photochemotherapy; | 2021 |
Mass Spectrometric Analysis of the Photobleaching of Protoporphyrin IX Used in Photodynamic Diagnosis and Therapy of Cancer.
Topics: Aminolevulinic Acid; Humans; Mass Spectrometry; Neoplasms; Photobleaching; Photochemotherapy; Photos | 2021 |
Efficiency of aminolevulinic acid (ALA)-photodynamic therapy based on ALA uptake transporters in a cell density-dependent malignancy model.
Topics: Adaptor Proteins, Signal Transducing; Aminolevulinic Acid; Antineoplastic Agents; Biological Transpo | 2021 |
Effect of 5-aminolevulinic acid on gene expression and presence of NKG2D receptor on NK cells.
Topics: Adult; Aminolevulinic Acid; Cell Differentiation; Cells, Cultured; Drug Screening Assays, Antitumor; | 2021 |
Design and Proof of Programmed 5-Aminolevulinic Acid Prodrug Nanocarriers for Targeted Photodynamic Cancer Therapy.
Topics: Aminolevulinic Acid; Gold; Humans; Metal Nanoparticles; Neoplasms; Photochemotherapy; Photosensitizi | 2017 |
Activity of phosphatase-sensitive 5-aminolevulinic acid prodrugs in cancer cell lines.
Topics: A549 Cells; Aminolevulinic Acid; Cell Line, Tumor; Cell Survival; Humans; Light; MCF-7 Cells; Micros | 2017 |
Modulating mitochondrial morphology enhances antitumor effect of 5-ALA-mediated photodynamic therapy both in vitro and in vivo.
Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Dynamins; Fl | 2017 |
Colloidal plasmonic gold nanoparticles and gold nanorings: shape-dependent generation of singlet oxygen and their performance in enhanced photodynamic cancer therapy.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Gold; Gold Colloid; Humans; Metal Nanoparticles; Nanostructur | 2018 |
A Simply Modified Lymphocyte for Systematic Cancer Therapy.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Humans; Lasers; Levulinic | 2018 |
Tip-loaded fast-dissolving microneedle patches for photodynamic therapy of subcutaneous tumor.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Animals; Cell Line, Tumor; Drug Carriers; Drug Deliv | 2018 |
A study of concentration changes of Protoporphyrin IX and Coproporphyrin III in mixed samples mimicking conditions inside cancer cells for Photodynamic Therapy.
Topics: Aminolevulinic Acid; Animals; Coproporphyrins; Equipment Design; Fiber Optic Technology; In Vitro Te | 2018 |
Case series showing the efficacy of 5-aminolaevulinic acid photodynamic therapy for epidermal growth factor receptor inhibitor-induced paronychia and pyogenic granuloma-like lesions.
Topics: Administration, Topical; Afatinib; Aged; Aminolevulinic Acid; ErbB Receptors; Female; Follow-Up Stud | 2019 |
Fluorescence Enhancement Effect of TiO
Topics: Aminolevulinic Acid; Cell Line, Tumor; Fluorescence; Humans; Nanoparticles; Neoplasms; Polyethylene | 2019 |
Quantification of PpIX-fluorescence of cerebral metastases: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Female; Fluorescent Dyes; Foll | 2019 |
Sonodynamic therapy inhibits angiogenesis and tumor growth in a xenograft mouse model.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Human Umbilical V | 2013 |
Synthesis and in vitro cellular uptake of 11C-labeled 5-aminolevulinic acid derivative to estimate the induced cellular accumulation of protoporphyrin IX.
Topics: Aminolevulinic Acid; Binding, Competitive; Carbon Radioisotopes; Cells, Cultured; Chromatography, Hi | 2013 |
Design and validation of a fiber optic point probe instrument for therapy guidance and monitoring.
Topics: Aminolevulinic Acid; Animals; Calibration; Carcinoma, Squamous Cell; Equipment Design; Fiber Optic T | 2014 |
Singlet oxygen and ROS in a new light: low-dose subcellular photodynamic treatment enhances proliferation at the single cell level.
Topics: Aminolevulinic Acid; Apoptosis; Cell Proliferation; HeLa Cells; Humans; Lasers; Neoplasms; Photochem | 2014 |
Preclinical characterization of 5-amino-4-oxo-[6-11C]hexanoic acid as an imaging probe to estimate protoporphyrin IX accumulation induced by exogenous aminolevulinic acid.
Topics: Aminocaproates; Aminolevulinic Acid; Animals; Cell Line, Tumor; Humans; Mice; Neoplasm Transplantati | 2014 |
The use of dipeptide derivatives of 5-aminolaevulinic acid promotes their entry to tumor cells and improves tumor selectivity of photodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Cell Survival; Dipeptides; Humans; Kinetics; Male; M | 2015 |
Multi-channel LED light source for fluorescent agent aided minimally invasive surgery.
Topics: Aminolevulinic Acid; Fluorescent Dyes; Humans; Indocyanine Green; Light; Minimally Invasive Surgical | 2014 |
eEF1A1 binds and enriches protoporphyrin IX in cancer cells in 5-aminolevulinic acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biological Availability; Cell Line; Gene Library; Hep G2 Cells; Humans; Neoplas | 2016 |
Tumor reactive ringlet oxygen approach for Monte Carlo modeling of photodynamic therapy dosimetry.
Topics: Aminolevulinic Acid; Humans; Models, Theoretical; Monte Carlo Method; Neoplasms; Photochemotherapy; | 2016 |
5-Aminolevulinic Acid Fluorescence in Detection of Peritoneal Metastases.
Topics: Aminolevulinic Acid; Cytoreduction Surgical Procedures; Female; Fluorescence; Follow-Up Studies; Hum | 2016 |
Nrf2-dependent induction of human ABC transporter ABCG2 and heme oxygenase-1 in HepG2 cells by photoactivation of porphyrins: biochemical implications for cancer cell response to photodynamic therapy.
Topics: Aminolevulinic Acid; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette T | 2008 |
5-aminolevulinic acid-conjugated gold nanoparticles for photodynamic therapy of cancer.
Topics: Aminolevulinic Acid; Animals; Coculture Techniques; Fibroblasts; Fibrosarcoma; Gold; Humans; Metal N | 2008 |
A brief history of photodynamic therapy in Wrocław.
Topics: Aminolevulinic Acid; History, 20th Century; History, 21st Century; Humans; Neoplasms; Photochemother | 2009 |
Enhancement of 5-Aminolevulinic acid-induced oxidative stress on two cancer cell lines by gold nanoparticles.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Cell Survival; Gold; Humans; Metal Nanoparticles; Microscopy, | 2009 |
Laser-induced effects in different biological samples.
Topics: Aminolevulinic Acid; Blood; Dihematoporphyrin Ether; HeLa Cells; Humans; Lasers; Microscopy, Confoca | 2010 |
Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy.
Topics: Aminolevulinic Acid; Heme; Humans; Molecular Structure; Neoplasms; Photochemotherapy; Photosensitizi | 2011 |
Drug delivery technologies and immunological aspects of photodynamic therapy.
Topics: Aminolevulinic Acid; Drug Carriers; Humans; Nanoparticles; Neoplasms; Photochemotherapy; Photosensit | 2011 |
Factors implicated in the assessment of aminolevulinic acid-induced protoporphyrin IX fluorescence.
Topics: Aminolevulinic Acid; Cell Communication; Cell Line, Tumor; Coculture Techniques; Collagen; Flow Cyto | 2013 |
Photodynamic effects of 5-aminolevulinic acid and its hexylester on several cell lines.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Mitochondria; Neopl | 2003 |
Reduction of theta-aminolevulinic acid dehydrase activity in the livers of tumor-bearing animals.
Topics: Aminolevulinic Acid; Animals; Hydro-Lyases; Liver; Neoplasms | 1957 |
INFLUENCES OF ANTICANCER AGENTS ON THE METABOLISM OF DELTA-AMINOLEVULINIC ACID IN MORMAL AND TUMOR-BEARING MICE.
Topics: Alkylating Agents; Amino Acids; Aminolevulinic Acid; Aminopterin; Animals; Antineoplastic Agents; Az | 1964 |
THE CHROMATOGRAPHIC SEPARATION, DETERMINATION, AND DAILY EXCRETION OF URINARY PORPHOBILINOGEN, AMINO ACETONE, AND DELTA-AMINOLEVULINIC ACID.
Topics: Acetone; Aminolevulinic Acid; Anemia; Anemia, Sickle Cell; Chromatography; Fluids and Secretions; Ho | 1964 |
PORPHOBILINOGEN AND DELTA-AMINOLEVULINIC ACID EXCRETION IN MULTIPLE SCLEROSIS.
Topics: Amino Acids; Aminolevulinic Acid; Demyelinating Diseases; Diagnosis, Differential; Fluids and Secret | 1965 |
Enhancement of photodynamic therapy by use of aminolevulinic acid/glycolic acid drug mixture.
Topics: Adenocarcinoma; Administration, Cutaneous; Aged; Aminolevulinic Acid; Animals; Antineoplastic Combin | 2004 |
Synthesis of 5-aminolevulinic acid (ALA) and its t-butyl ester for the fluorescence detection of early cancer.
Topics: Aminolevulinic Acid; Early Diagnosis; Fluorescence; Humans; Neoplasms; Sensitivity and Specificity | 2005 |
Clinical pharmacokinetics of the PDT photosensitizers porfimer sodium (Photofrin), 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (Photochlor) and 5-ALA-induced protoporphyrin IX.
Topics: Administration, Topical; Aminolevulinic Acid; Chlorophyll; Dihematoporphyrin Ether; Fluorometry; Hal | 2006 |
Phototherapy and malignancy: possible enhancement by iron administration and hyperbaric oxygen.
Topics: Aminolevulinic Acid; Combined Modality Therapy; Heme; Heme Oxygenase-1; Humans; Hyperbaric Oxygenati | 2006 |
5-Aminolaevulinic acid (ALA) induced formation of different fluorescent porphyrins: a study of the biosynthesis of porphyrins by bacteria of the human digestive tract.
Topics: Aminolevulinic Acid; Bacteria; Bacteriological Techniques; Digestive System; Dimerization; Fluoresce | 2007 |
Glycoside esters of 5-aminolevulinic acid for photodynamic therapy of cancer.
Topics: Aminolevulinic Acid; Cell Line; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Esterases; | 2008 |
Pharmacokinetics of 5-aminolevulinic-acid-induced porphyrins in tumour-bearing mice.
Topics: Aminolevulinic Acid; Animals; Dose-Response Relationship, Drug; Humans; Injections, Intravenous; Mic | 1996 |
Accumulation of porphyrins in plasma and tissues of dogs after delta-aminolevulinic acid administration: implications for photodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Coproporphyrins; Dogs; Liver; Male; Neoplasms; Pancreas; Photochemothe | 1996 |
Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture.
Topics: Adenocarcinoma; Aminolevulinic Acid; Animals; Colonic Neoplasms; Cricetinae; Cricetulus; Drug Screen | 1997 |
On the carcinogenic risk evaluation of diesel exhaust: benzene in airborne particles and alterations of heme metabolism in lymphocytes as markers of exposure.
Topics: Adult; Air Pollutants; Aminolevulinic Acid; Benzene; Biomarkers; Heme; Humans; Inhalation Exposure; | 1998 |
Ambulant photodynamic therapy of superficial malignomas with 5-ALA in combination with folic acid and use of noncoherent light.
Topics: Administration, Topical; Ambulatory Care; Aminolevulinic Acid; Folic Acid; Humans; Neoplasms; Photoc | 1999 |
Relationship of delta-aminolevulinic acid-induced protoporphyrin IX levels to mitochondrial content in neoplastic cells in vitro.
Topics: Aminolevulinic Acid; Animals; Electron Transport Complex IV; Ferrochelatase; Fluorescent Dyes; Human | 1999 |
Diagnosing cancer in vivo.
Topics: Aminolevulinic Acid; Automation; Biopsy; Colonic Neoplasms; Endoscopy; Humans; Microscopy, Confocal; | 2001 |
Routine experimental system for defining conditions used in photodynamic therapy and fluorescence photodetection of (non-) neoplastic epithelia.
Topics: Aminolevulinic Acid; Animals; Cell Death; Culture Techniques; Humans; Hydrogen-Ion Concentration; Mi | 2001 |
Alterations of heme metabolism in lymphocytes and metal content in blood plasma as markers of diesel fuels effects on human organism.
Topics: 5-Aminolevulinate Synthetase; Adult; Aminolevulinic Acid; Biomarkers; DNA; Female; Ferrochelatase; H | 2002 |
[Excretion of delta-aminolevulinic acid during combined radiotherapy of patients with cervix carcinoma. 2. Medical check-ups for lead in the Vienna area among various occupational and personal groups].
Topics: Aminolevulinic Acid; Bone and Bones; Cobalt Radioisotopes; Extracorporeal Circulation; Female; Human | 1975 |
Systemic MEK inhibition enhances the efficacy of 5-aminolevulinic acid-photodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Benzimidazoles; Cell Line, Tumor; Female; Humans; Levulinic Acids; Mal | 2019 |
Amylase-Protected Ag Nanodots for in vivo Fluorescence Imaging and Photodynamic Therapy of Tumors.
Topics: Aminolevulinic Acid; Amylases; Animals; Cell Line, Tumor; Fluorescence; Humans; Levulinic Acids; Mic | 2020 |
Metronomic photodynamic therapy using an implantable LED device and orally administered 5-aminolevulinic acid.
Topics: Administration, Metronomic; Administration, Oral; Aminolevulinic Acid; Animals; Antineoplastic Agent | 2020 |
Tumor-targeting core-shell structured nanoparticles for drug procedural controlled release and cancer sonodynamic combined therapy.
Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; Artemisinins; Delayed-Action Preparations; Drug | 2018 |